Bram Brouwers

机构：Eli Lilly (United States) · ORCID：0000-0002-3676-5051

发表论文 36 篇 · 总被引 2725 次 · h-index 19

代表论文

• Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis (2024 · New England Journal of Medicine · 被引 943)
• Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial (2022 · The Lancet Diabetes & Endocrinology · 被引 503)
• Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024 · Nature Medicine · 被引 293)
• Exercise training elicits superior metabolic effects when performed in the afternoon compared to morning in metabolically compromised humans (2020 · Physiological Reports · 被引 119)
• Distinct lipid droplet characteristics and distribution unmask the apparent contradiction of the athlete's paradox (2018 · Molecular Metabolism · 被引 113)
• Effects of exercise training on intrahepatic lipid content in humans (2016 · Diabetologia · 被引 95)